MonoSol Rx Responds to Civil Complaint Filed by States Attorneys General
N.J., September 23, 2016 – MonoSol Rx develops and manufactures
FDA-approved pharmaceutical film products. The company licenses its
PharmFilm® drug delivery technology to improve patient treatment and to
address unmet needs. MonoSol Rx was notified last night of a civil
complaint filed earlier yesterday by thirty five U.S. states and the
District of Columbia, alleging violations of federal and state
antitrust and consumer protection laws related to Suboxone®
(buprenorphine and naloxone) sublingual film.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm® can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, please visit www.monosolrx.com.